Hannah Valantine - 06 Mar 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Hannah Valantine
Issuer symbol
BBIO
Transactions as of
06 Mar 2025
Net transactions value
-$203,843
Form type
4
Filing time
10 Mar 2025, 16:43:50 UTC
Previous filing
25 Jun 2024
Next filing
06 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise $215,656 +12,875 +730% $16.75 14,639 06 Mar 2025 Direct F1
transaction BBIO Common Stock Sale $419,500 -12,875 -88% $32.58 1,764 06 Mar 2025 Direct F1, F2
holding BBIO Common Stock 3,433 06 Mar 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (right to buy) Options Exercise $0 -12,875 -25% $0.000000 38,626 06 Mar 2025 Common Stock 12,875 $16.75 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024.
F2 Represents the weighted average sale price of the shares sold from $32.17 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3 The stock option vests in three annual installments starting on June 21, 2024 and ending on June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors.